Leflunomide interferes with pyrimidine nucleotide biosynthesis

Inflammation Research

Volumn 44, Issue 8, 1995, Pages 317-322

  Cherwinski, H M ^a   Byars, N ^a   Ballaron, S J ^a   Nakano, G M ^a   Young, J M ^a   Ransom, J T ^a  

^a ROCHE BIOSCIENCE   (United States)

Author keywords

DHOD; Dihydro orotate dehydrogenase; Leflunomide; Purine nucleotide; T cell

Indexed keywords

CYTIDINE; DIHYDROOROTATE DEHYDROGENASE; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; MITOGENIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PURINE NUCLEOTIDE; URIDINE;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CELL STIMULATION; CELL TRANSFORMATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; LYMPHOCYTE; MEASUREMENT; MOUSE; NONHUMAN; NUCLEOTIDE METABOLISM; PYRIMIDINE SYNTHESIS; RAT; SIGNAL TRANSDUCTION; SPLEEN CELL; T LYMPHOCYTE;

ANIMAL; CONCANAVALIN A; FEMALE; HUMAN; IMMUNOSUPPRESSIVE AGENTS; IN VITRO; INDICATORS AND REAGENTS; ISOXAZOLES; MICE; MICE, INBRED BALB C; PC12 CELLS; PYRIMIDINE NUCLEOTIDES; RATS; SPLEEN; TETRAZOLIUM SALTS; THIAZOLES; TUMOR CELLS, CULTURED;

EID: 0029144186     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/BF01796261     Document Type: Article

References (25)

1. Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection
2. The influence of leflunomide on cell cycle, IL-2-receptor (IL-2-r) and its gene expression
3. Suppression of natural xenophile antibodies with the novel immunomodulating drug leflunomide
4. Immunosuppressive effects of leflunomide in a cardiac allograft model
5. Prolongation of allogeneic transplanted skin grafts and induction of tolerance by leflunomide, a new immunosuppressive isoxazole derivative
6. Immunomodulation of proteoglycaninduced progressive polyarthritis by leflunomide
7. Leflunomide therapy following penetrating keratoplasty in the rat
8. Promotion of corneal allograft survival with leflunomide
9. Therapeutic activity of leflunomide in acute and chronic relapsing experimental allergic encephalomyelitis
10. The efficacy of leflunomide in s-antigen-induced autoimmune uveitis
11. Efficacy and safety of leflunomide in the treatment of patients with rheumatoid arthritis
12. Effect of leflunomide on constitutive and inducible pathways of cellular eicosanoid generation
13. Leflunomide, a novel immunosuppressive agent. The mechanism of inhibition of T cell proliferation
14. The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism
15. Inhibition of interleukin 2 (IL-2)-stimulated tyrosine kinase activity by leflunomide
16. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomid
17. Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase
18. The unique immunosuppressive activity of brequinar sodium
19. Mechanisms of action of mycophenolic acid
20. Antigen recognition by H-2 restricted T Cells. I. Cell-free antigen processing
21. Characterization of the m4 muscarinic receptor Ca2+ response in a subclone of PC12 cells by single cell flow cytometry. Inhibition of the response by bradykinin
22. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays
23. Leflunomide, a novel immunomodulatory agent: In vitro analyses of the mechanism of immunosuppression
24. Structure-activity relationship of quinoline carboxylic acids. A new class of inhibitors of dihydroorotate dehydrogenase
25. Lymphocyte selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: Role of deoxyguanosine nucleotide depletion